Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: A prospective cohort study

Assessment of Fracture Risk and Its Application to screening for Postmenopausal Osteoporosis, 1994, vol. 843, 1 Coresh, 2003, Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. American Journal of Kidney Diseases: the official Journal of the National Kidney Foundation, Comparative Study Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S., 41, 1 Cosman, 2016, Romosozumab Treatment in Postmenopausal Women with Osteoporosis. The New England journal of medicine, Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t, 375, 1532 Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. The New England journal of medicine. Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Aug 20 2009;361(8):756–65. (Epub 2009/08/13). Cummings, 2018, Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension, Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research. Randomized Controlled Trial Research Support, Non-U.S. Gov’t, 33, 190, 10.1002/jbmr.3337 Diez-Perez, 2019, Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: a systematic review and meta-analysis, Bone. Meta-Analysis Research Support, Non-U.S. Gov’t Systematic Review, 120, 1 Ebina, 2020, Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis, Bone. Nov, 140, 115574, 10.1016/j.bone.2020.115574 Gasser, 2000, PTH and interactions with bisphosphonates, J. Musculoskelet. Neuronal Interact., 1, 53 Holick, 2012, Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited, The Journal of Clinical Endocrinology and Metabolism. Research Support, Non-U.S. Gov’t, 97, 1153, 10.1210/jc.2011-2601 Ishibashi, 2017, Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: a phase 2 study, Bone. Clinical Trial, Phase II Randomized Controlled Trial, 103, 209 Kendler, 2019, Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab, Osteoporos Int. Clinical Trial, Phase II Multicenter Study Randomized Controlled Trial, 30, 2437 Langdahl, 2017, Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial, Lancet., 390, 10.1016/S0140-6736(17)31613-6 Leder, 2015, Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial, vol. 386 Marcus, 2003, The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis, J Bone Miner Res. Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov’t, vol. 18, 18 McClung, 2005, Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Archives of internal medicine, 165 Nakamura, 2017, Increased serum 25(OH)D3 levels in post-menopausal Japanese women with osteoporosis after 3-year bisphosphonate treatment, Tohoku J. Exp. Med., 242, 241, 10.1620/tjem.242.241 Nenonen, 2005, Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover, Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research. Randomized Controlled Trial Research Support, Non-U.S. Gov’t, 20, 1804, 10.1359/JBMR.050403 Ominsky, 2015, Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats, Bone. Research Support, Non-U.S. Gov’t, 81, 380 Orimo, 2012, Japanese 2011 guidelines for prevention and treatment of osteoporosis--executive summary, Arch. Osteoporos., 7, 3, 10.1007/s11657-012-0109-9 Payne RB, Little AJ, Williams RB, Milner JR. Interpretation of serum calcium in patients with abnormal serum proteins. Br. Med. J. Dec 15 1973;4(5893):643–6. (Epub 1973/12/15). Saag, 2017, Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. The New England journal of medicine, Clinical Trial, Phase III Comparative Study Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t, 377, 1417 Shepherd, 2006, Comparison of BMD precision for prodigy and Delphi spine and femur scans. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, Comparative Study Multicenter Study Research Support, Non-U.S. Gov’t, 17, 1303 Soen, 2013, Diagnostic criteria for primary osteoporosis: year 2012 revision, J. Bone Miner. Metab., 31, 247, 10.1007/s00774-013-0447-8 Tamaki, 2017, Total 25-hydroxyvitamin D levels predict fracture risk: results from the 15-year follow-up of the Japanese Population-based Osteoporosis (JPOS) Cohort Study, Osteoporos. Int., 28, 1903, 10.1007/s00198-017-3967-6 Taylor, 2016, Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats, Bone. Research Support, Non-U.S. Gov’t, 84, 148